The Phase 3 trial of Apitegromab showed statistically significant improvement in motor function.
More Stories
These 12 stocks stand behind Goldman’s S&P 500 optimism — and Micron stands out
Goldman expects corporate profit margins to increase through 2026. These companies’ gross margins have already improved for four straight quarters.
Fed rate cuts may make ether more attractive after being left behind by bitcoin
As the Federal Reserve is expected to further lower its key interest rate after delivering a 50 basis points rate...
Housing sentiment jumps to highest level in over two years, Fannie Mae says
A record number of consumers expect mortgage rates to fall over the next year. They’re also bracing for an increase...
After Hurricane Helene, should I buy property in Florida at a reduced price? Is now a good time to strike a deal?
“Many of those owners were not insured or underinsured.”
Yet another bullish call on Nvidia’s stock? Don’t ignore this one.
A Melius Research analyst says “you still get some eye rolls when you reiterate this buy,” but the setup for...
Apple’s stock draws a downgrade as AI optimism may be very premature
A Jefferies analyst says it will take time for smartphone technology to truly support AI. That means sales expectations for...